Inoviv announces the launch of MasterKey™, which enables researchers to select specific proteins from a comprehensive, pre-characterized catalog of thousands of...

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, announced the launch of the new OFF-X™ platform. The enhanced solution offers a seamless user experience and...

Galderma announced that it has completed its European decentralized procedure (DCP), resulting in a positive decision for RelfydessTM (RelabotulinumtoxinA –...

Lipella Pharmaceuticals Inc. a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the enrollment of the first patients in its multi-center...

NewAmsterdam Pharma Company N.V a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated...

AIM ImmunoTech Inc. announced the next CEO Corner segment has been published on the Company’s website. In the CEO Corner segment, AIM Chief Executive Officer Thomas Equels provides an overview of...

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced  that the independent Data and...

Innocan Pharma Corporation a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor...

Astellas Pharma Inc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of PADCEV™...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and Sanofi announced an update to the timing for the anti-TL1A, duvakitug (formerly known as TEV-’574/SAR447189) program...

T3D Therapeutics, Inc., a clinical stage drug development company engaged in the development of a new orally administered treatment for Alzheimer's disease (AD), announced that CEO, John Didsbury, will...

Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, including Alzheimer's...